Sinopharm : PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS AND SUPERVISORS

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(A joint stock limited company incorporated in the People's Republic of China with limited liability

and carrying on business in Hong Kong as 國控股份有限公司 )

(Stock Code: 01099)

PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS AND SUPERVISORS

The Board hereby announces that as the term of office of the fourth session of the Board will expire on 20 September 2020, it resolved at the meeting of the Board held on 21 August 2020 to propose to re-elect Mr. Li Zhiming, Mr. Yu Qingming and Mr. Liu Yong as executive Directors of the fifth session of the Board; to re-elect Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli as non-executive Directors of the fifth session of the Board; and to re-elect Mr. Zhuo Fumin and Mr. Chen Fangruo as independent non-executive Directors of the fifth session of the Board. In addition, the Board also proposed at the same meeting to appoint Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng as new independent non-executive Directors of the fifth session of the Board.

The Board further announces that as the term of office of the fourth session of the Supervisory Committee will also expire on 20 September 2020, the Supervisory Committee resolved at the meeting of the Supervisory Committee held on 21 August 2020 to propose to re-elect Ms. Li Xiaojuan as shareholder representative Supervisor of the fifth session of the Supervisory Committee. The Supervisory Committee also proposed at the same meeting to appoint Mr. Wu Yifang and Mr. Liu Zhengdong as new independent Supervisors of the fifth session of the Supervisory Committee.

In accordance with the Articles of Association, the above proposed re-election and appointment of Directors and Supervisors are subject to the approval by the Shareholders at the general meeting of the Company, while the employee representative Supervisors of the fifth session of the Supervisory Committee shall be elected democratically by the employees of the Company and is not subject to the Shareholders' approval. An extraordinary general meeting of the Company will be held in due course to, among others, seek the approval of the Shareholders on the re-election

1

and appointment of Directors and Supervisors.

Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng and Mr. Liu Zhengdong, the independent non- executive Directors of the fourth session of the Board, will retire upon the appointment of Directors of the fifth session of the Board being approved at the general meeting of the Company. Mr. Yao Fang and Mr. Tao Wuping, the independent Supervisors of the fourth session of the Supervisory Committee, will retire upon the appointment of Supervisors of the fifth session of the Supervisory Committee being approved at the general meeting of the Company. The Board would like to express its sincere gratitude to the contributions made by Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng and Mr. Liu Zhengdong to the Company during their tenure as Directors and also express its sincere gratitude to the contributions made by Mr. Yao Fang and Mr. Tao Wuping to the Company during their tenure as Supervisors.

Proposed Re-election and Appointment of Directors

The board (the "Board") of directors (the "Director(s)") of Sinopharm Group Co. Ltd. (the "Company", together with its subsidiaries, collectively as the "Group") hereby announces that as the term of office of the fourth session of the Board will expire on 20 September 2020, it resolved at the meeting of the Board held on 21 August 2020 to propose to re-elect Mr. Li Zhiming, Mr. Yu Qingming and Mr. Liu Yong as executive Directors of the fifth session of the Board; to re-elect Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli as non-executive Directors of the fifth session of the Board; and to re-elect Mr. Zhuo Fumin and Mr. Chen Fangruo as independent non-executive Directors of the fifth session of the Board. In addition, the Board also proposed at the same meeting to appoint Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng as new independent non-executive Directors of the fifth session of the Board.

Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng have all confirmed their compliance with the independence guidelines set out in Rule 3.13 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Hong Kong Listing Rules"). When considering the candidates of independent non-executive Directors for the fifth session of the Board, the Board has considered the independence confirmations of Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng and their skills, background, knowledge and experience. In particular, Mr. Zhuo Fumin has extensive experience in capital markets and financial investment, Mr. Chen Fangruo has extensive experience in strategic management, Mr. Li Peiyu has extensive experience in corporate management and macroeconomic research, Mr. Wu Tak Lung has extensive experience in finance, and Mr. Yu Weifeng has extensive experience in law. Their different education, background, professional experience and practice enable them to provide relevant valuable insights and contributions to the diversity of the Board.

In accordance with the articles of association of the Company (the "Articles of Association"), the above proposed re-election and appointment of Directors are subject to the approval by the shareholders of the Company (the "Shareholders") at the general meeting of the Company.

2

Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng and Mr. Liu Zhengdong, the independent non- executive Directors of the fourth session of the Board, will retire upon the appointment of Directors of the fifth session of the Board being approved at the general meeting. The Board would like to express its sincere gratitude to the contributions made by Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng and Mr. Liu Zhengdong to the Company during their tenure as Directors.

Upon the above proposed re-election and appointment of Directors of the fifth session of the Board being approved by the Shareholders, the Company will enter into a service contract with each of them. The term of office of each of them as a Director of the fifth session of the Board will be three years from the date of obtaining the Shareholders' approval. The remuneration of each of them for serving as an executive Director, non-executive Director or independent non-executive Director of the fifth session of the Board will be determined by the Board according to the authorization granted by the Shareholders at the annual general meeting of the Company held on 11 June 2020 and in accordance with the Company's remuneration policies regarding the executive Directors, non- executive Directors and independent non-executive Directors, respectively.

Biographies of the Director candidates for the fifth session of the Board are set out in Appendix I to this announcement.

Proposed Re-election and Appointment of Supervisors

The Board further announces that as the term of office of the fourth session of the supervisory committee (the "Supervisory Committee") will also expire on 20 September 2020, the Supervisory Committee resolved at the meeting of the Supervisory Committee held on 21 August 2020 to propose to re-elect Ms. Li Xiaojuan as shareholder representative Supervisor of the fifth session of the Supervisory Committee. The Supervisory Committee also proposed at the same meeting to appoint Mr. Wu Yifang and Mr. Liu Zhengdong as new independent Supervisors of the fifth session of the Supervisory Committee.

In accordance with the Articles of Association, the above proposed re-election and appointment of Supervisors are subject to the approval by the Shareholders at the general meeting of the Company, while the employee representative Supervisors of the fifth session of the Supervisory Committee shall be elected democratically by the employees of the Company and are not subject to the Shareholders' approval.

Mr. Yao Fang and Mr. Tao Wuping, the independent Supervisors of the fourth session of the Supervisory Committee, will retire upon the appointment of Supervisors of the fifth session of the Supervisory Committee being approved at the general meeting of the Company. The Board would like to express its sincere gratitude to the contributions made by Mr. Yao Fang and Mr. Tao Wuping to the Company during their tenure of service as Supervisors.

Upon the above proposed re-election and appointment of Supervisors of the fifth session of the Supervisory Committee being approved by the Shareholders, the Company will enter into a service contract with each of them. The term of office of each of them as a Supervisor of the fifth session of the Supervisory Committee will be three years from the date of obtaining the Shareholders' approval. Ms. Li Xiaojuan will not receive any remuneration from the Company in her capacity as shareholder representative Supervisor of the Company. The remuneration of each of the independent Supervisors of the fifth Session of the Supervisory Committee will be determined by the Supervisory Committee

3

according to the authorization granted by the Shareholders at the annual general meeting of the Company held on 11 June 2020 and with reference to their duties in the Company, the Company's performance and the prevailing market condition.

Biographies of the shareholder representative Supervisor and independent Supervisor candidates for the fifth session of the Supervisory Committee are set out in Appendix II to this announcement.

An extraordinary general meeting of the Company will be held in due course to, among others, seek the approval of the Shareholders on the re-election and appointment of Directors and Supervisors.

By order of the Board

Sinopharm Group Co. Ltd.

Li Zhiming

Chairman

Shanghai, the PRC

21 August 2020

As at the date of this announcement, the executive directors of the Company are Mr. Li Zhiming, Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong, Mr. Zhuo Fumin and Mr. Chen Fangruo.

• The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".

4

APPENDIX I BIOGRAPHIES OF THE DIRECTOR CANDIDATES FOR THE FIFTH SESSION OF THE BOARD

Mr. Li Zhiming, aged 58, is currently an executive Director, the Chairman (Legal Representative), and Deputy Secretary of Party Committee of the Company. Mr. Li has more than 38 years of working experience, over 34 years of which is management experience in the pharmaceutical and healthcare products industry. Mr. Li graduated from the economic management discipline of the Urumqi Branch of Xi'an Military Academy with associate degree in July 1997. Mr. Li was qualified as a senior economist and a chief pharmacist. Mr. Li was the deputy director of finance department of Xinjiang New & Special Ethnic Drug Store, staff of audit department of Xinjiang Pharmaceutical Administration Bureau, deputy general manager and chief accountant of Xinjiang Pharmaceutical Industry and Trade Company, chief accountant and deputy general manager of Xinjiang New & Special Ethnic Drug Corporation, and deputy director of the office of the preparatory and leading group of Xinjiang Pharmaceutical Administration Bureau steering the construction of the group entity, and general manager of Xinjiang New & Special Ethnic Drug Corporation from July 1985 to February 2000. Mr. Li held senior management positions such as chairman, general manager and secretary of party committee of Xinjiang Pharmaceutical Group Company from February 2000 to February 2009, and served as the chairman, general manager and secretary of party committee of Sinopharm Group Xinjiang Medicines Co., Ltd. from February 2009 to May 2013. Mr. Li served as the vice president of the Company from May 2010 to November 2013, and served as the president and deputy secretary of party committee from November 2013 to March 2017, and has served as executive director since January 2014 and the chairman, president and secretary of party committee from March 2017 to November 2017, and served as the chairman and secretary of party committee from November 2017 to November 2018, and has served as the chairman and deputy secretary of party committee since November 2018. Mr. Li is currently the director and general manager of Sinopharm Industrial Investment Co., Ltd. ("Sinopharm Investment"), the director of China National Accord Medicines Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 000028 (A Share) / 200028 (B Share))("Sinopharm Accord") and China National Medicines Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600511) ("National Medicines"), vice chairman of Shanghai Shyndec Pharmaceutical Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600420), and also takes senior management positions in a number of subsidiaries of the Company.

Mr. Yu Qingming, aged 56, is currently an executive Director and Secretary of Party Committee of the Company. Mr. Yu has over 33 years of working experience, especially in the management of pharmaceuticals, health products and medical devices, and holds the professional title of senior engineer. Mr. Yu graduated from Shanghai Medical Equipment College (now known as Shanghai University of Medicine and Health Sciences) in 1987, and graduated from the Party School of the Central Committee of C.P.C majoring in economic management in July 2001 with a master's degree. From July 1987 to April 1990, Mr. Yu successively served as secretary of Communist League Branch at Beijing Pharmaceutical Station of CNPGC, secretary to the general manager and secretary to the Administrative Party Branch of China Medical Instrument Corporation. From April 1990 to February 1997, he served in the State Pharmaceutical Administration, serving as deputy principle clerk, principle clerk and deputy department secretary of the General Office. From February 1997 to December 2009, he successively served as deputy general manager of the China sales department and manager of the corporate management department, assistant to chairman, vice president and executive president of Zhuhai United Laboratories Co., Ltd. and executive president of Federal

5

Pharmaceutical International Holdings Limited. Mr. Yu was the director, general manager and party secretary of China Medical Instrument Corporation from December 2009 to August 2010. Mr. Yu has taken senior management positions of China National Scientific Instruments and Materials Co., Ltd. and China National Medical Device Co., Ltd. since August 2010, and currently served as the chairman of China National Scientific Instruments and Materials Co., Ltd. and China National Medical Device Co., Ltd.. Mr. Yu has served as secretary of party committee of the Company since November 2018 and executive Director of the Company since December 2018. Mr. Yu is currently also a member of the 13th Beijing Chaoyang District of Chinese People's Political Consultative Conference, a representative of the National People's Congress, vice president of China Association for Medical Devices Industry, vice chairman of China Association of Medical Equipment, vice president of China Chamber of Commerce for Import and Export of Medicines and Health Products, and vice president of China Association for Vaccines etc.

Mr. Liu Yong, aged 51, is currently an executive Director, t h e President and Deputy Secretary of Party Committee of the Company. Mr. Liu has over 28 years of working experience, over 25 years of which is management experience in the pharmaceutical and healthcare products industry. Mr. Liu obtained a bachelor's degree in science, majoring in business administration of pharmaceutical enterprises, from China Pharmaceutical University in July 1992, a master's degree in business administration from Fudan University in January 2000 and a doctoral degree in social and administrative pharmacy from China Pharmaceutical University in June 2016. Mr. Liu is a chief pharmacist and a practicing pharmacist. Mr. Liu was employed at Shanghai Pharmaceutical Station from July 1992 to July 1999, and served as the deputy general manager at the marketing department of China National Pharmaceutical Group Shanghai Co., Ltd. and the deputy general manager of Shanghai Guoda Drug Chain Store Co., Ltd. from July 1999 to April 2003. Mr. Liu was the general manager and secretary of Party Committee of Sinopharm Holding Shenyang Co., Ltd. from April 2003 to November 2009. Mr. Liu served as vice president of the Company from January 2009 to November 2017, and has served a s executive Director and president since November 2017, and deputy

secretary of party committee since January 2018. During this period, he served as general

legal counsel of the Company from January 2014 to March 2018, and was also secretary to the Board of the Company from October 2016 to November 2017, and served as both joint company secretary and authorized representative of the Company from October 2016 to August 2018. Mr. Liu is also the chairman of Sinopharm Investment and National Medicines, and Sinopharm Accord, and also takes senior management positions in a number of subsidiaries of the Company.

Mr. Chen Qiyu, aged 48, is currently a non-executive Director and vice chairman of the Company. He joined the Company in January 2003, and had served as the chief Supervisor of the Company until May 2010. He has served as a non-executive Director o f t h e C o m p a n y since May 2010 and has been the vice chairman since November 2013. Mr. Chen has over 27 years of working experience. He obtained a bachelor's degree in genetics from Fudan University in July 1993 and a master's degree of advanced business administration from China Europe International Business School in September 2005. Mr. Chen was previously the chief financial

6

officer, the board secretary, general manager, president and vice chairman of the board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (a company listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange, stock code: 02196 (H Share) /600196 (A Share)) ( " Fosun Pharmaceutical" ) from July 1998 to May 2010, and has been its director and chairman since May 2005 and June 2010, respectively. Mr. Chen has served as the vice president, co-president and co-chief executive officer of Fosun International Limited (a company listed on the Hong Kong Stock Exchange, stock code: 00656) since August 2010, and has served as its executive director since July 2015. He has served as the vice president and co- president of Shanghai Fosun High Technology (Group) Co., Ltd. ("Fosun High Technology") since January 2011, and has served as its director since July 2015 and has served as its Chairman since November 2017. Mr. Chen has been a director of Beijing Sanyuan Food Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600429) since September 2015. Mr. Chen has served as a director of Shanghai Henlius Biotech, Inc. (a company listed on the Hong Kong Stock Exchange, stock code: 02696) ( " Henlius" ) since January 2013 and as chairman of the company's board of directors since December 2018; served as a non- executive director of Babytree Group (a company listed on the Hong Kong Stock Exchange, stock code: 01761) since June 2018; and served as the co-chairman of New Frontier Health Corporation (a company listed on the New York Stock Exchange, stock code: NFH) since December 2019. Mr. Chen served as the supervisor, director as well as the director and general manager of Sinopharm Investment from July 2008 to March 2014 successively, and has served as the vice chairman of the same since March 2014 till now. Mr. Chen is currently also the chairman of China Medical Pharmaceutical Material Association, vice chairman of China Association for Pharmaceutical Innovation, honorary chairman and chief supervisor of Shanghai Biopharmaceutics Industry Association, the vice-chief of Shanghai Society of Genetics and the standing member of the 13th Shanghai Committee of the Chinese People's Political Consultative Conference.

Mr. Ma Ping, aged 64, is currently a non-executive director of the Company. He joined the Company and has served as a non-executive Director of the Company since October 2016. Mr. Ma has over 37 years of working experience and currently serves as an external director of China National Pharmaceutical Group Corporation Ltd. ("CNPGC"). Mr. Ma received a bachelor's degree from chemistry department of Fudan University in 1982. Mr. Ma served as principal clerk, engineer, vice director and director of Ministry of Labor and Personnel, National Pharmaceutical Administration, State Planning Commission, respectively from February 1982 to March 1992. He served as department manager, project manager, general manager of London Export Corporation, Hoechst (China), Lotus Healthcare, respectively from March 1992 to April 1994. He co-founded and served as managing director of BMP from April 1994 to October 1996. He served as investment director, business development director of Sinogen International Ltd. from October 1996 to May 1998. He served as vice president, COO, China general manager of United Medical Industrial Group from May 1998 to March 2000. He served as director, vice general manager of Tonghua Golden-horse Group (a company listed on the Shenzhen Stock Exchange, stock code: 000766) from March 2000 to September 2001. He served as director, general manager of BMP (a company listed on NASDAQ, stock code: BJGP) from September 2001 to December 2005. He served as director and general manager of BioPro Pharmaceutical Inc. from December 2005 to December 2011. He has been serving as director of

7

BioPro Pharmaceutical Inc. and project consultant of Principle Capital since December 2011, and has been serving as an external director of CNPGC since May 2016. Mr. Ma is also the director of China National Biotec Group Co., Ltd..

Mr. Hu Jianwei, aged 46, is currently a non-executive Director of the Company. He has served as a non-executive Director of the Company since he joined the Company in December 2018. Mr. Hu worked at government agencies for a long time from July 1994 to November

2017. He has in-depth research on macroeconomic operation and management and is familiar with medical and health work. He has served as a member of party committee and deputy general manager of CNPGC since December 2017, and general counsel since January 2019, mainly responsible for work such as strategic planning, branding, operation and legal affairs.

Mr. Deng Jindong, aged 56, is currently a non-executive Director of the Company. He has been a non-executive Director since he joined the Company in August 2007. Mr. Deng has over 32 years of working experience, over 27 years of which is financial management experience. Mr. Deng obtained a bachelor's degree in economics from Hangzhou Electronics Industry Institution (currently known as Hangzhou Dianzi University) in July 1986 and a master's degree in economics from Central Institute of Finance and Economics (currently known as Central University of Finance & Economics) in January 1991. He is a non-practicing PRC certified public accountant. Mr. Deng was previously the chief financial officer of Economic Information Network Data Co., Ltd., senior audit manager of Taikang Life Insurance Co., Ltd. and the head of the finance department of CNPGC from April 2000 to October 2001, from October 2001 to October 2002 and from October 2002 to October 2004, respectively. Mr. Deng has been the chief accountant of CNPGC from October 2004 to May 2017, and has served as its vice general manager since May 2017. Mr. Deng served as a director and chief financial officer, and a director of Sinopharm Investment from July 2008 to August 2015 and from August 2015 to January 2016, respectively. He has also been its chairman since January 2016.

Mr. Wen Deyong, aged 49, is currently a non-executive Director of the Company. Mr. Wen has served as a non-executive Director of the Company since September 2017. Mr. Wen graduated from Donghua University and received a master's degree in business administration in December 2007. Mr. Wen is currently the executive vice president of Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. and vice chairman of Fosun Pharmaceutical. Mr. Wen served as the technician in water-needle workshop of Chongqing Pharmaceutical Co., Ltd. No.6 Factory, the sales outworker in sales department, the sales director in sales company, the general manager in No.2 marketing department of Chongqing Yaoyou Pharmaceutical Co., Ltd., the general manager of northern unit of Chongqing Haisiman Company, the vice president and president of Chongqing Yaoyou Pharmaceutical Co., Ltd from September 1995 to May 2016. Mr. Wen has served as a director of Sinopharm Investment since March 2019, a director of National Medicines since May 2019, and a supervisor of Sinopharm Accord since May 2019.

Ms. Guan Xiaohui, aged 49, is currently a non-executive Director of the Company. She has served as a non-executive Director of the Company since she joined the Group in March 2019. Ms. Guan obtained a bachelor's degree in economics from Jiangxi University of Finance and Economics and obtained a master's degree in accounting for senior accountant from the Chinese

8

University of Hong Kong in December 2007. Ms. Guan joined Fosun Pharmaceutical in May 2000 and currently serves as the senior vice president and chief financial officer. Before joining Fosun Pharmaceutical and its subsidiaries, Ms. Guan worked at Jiangxi Provincial Branch of the Industrial and Commercial Bank of China from July 1992 to May 2000. Ms. Guan served as the supervisor of Sinopharm Accord. Currently, Ms. Guan is also a supervisor of Sinopharm Investment. Ms. Guan is qualified as Chinese Certified Public Accountant and a member of The Association of Chartered Certified Accountants.

Ms. Feng Rongli, aged 45, is currently a non-executive Director of the Company. She has served as a non-executive Director of the Company since June 2020. Ms. Feng graduated from Shanghai University with a major in microcomputer application in July 1996. In February 2002, she obtained a master's degree in business administration from Columbia Southern University. Ms. Feng served as a human resources supervisor of Sealed Air Packaging (Shanghai) Co., Ltd. (希悅爾包裝（上海）有限公司) from July 1996 to April 2000, a human resources manager of Grundfos Pumps (Shanghai) Co., Ltd. ( 格蘭富水泵（上海）有限公司 ) from April 2000 to November 2002, the Asia-Pacific human resources manager of Emerson Electric (China) Holdings Co., Ltd. (艾默生電氣（中國）投資有限公司) from November 2002 to July 2006, the China human resources planning manager of Dow Chemical (China) Co., Ltd. (陶氏化學（中國） 有限公司) from August 2006 to November 2009, the director of human resources of Shanghai Roche Pharmaceutical Co., Ltd. (上海羅氏製藥有限公司) from November 2009 to January 2015, and the senior director of human resources at F. Hoffmann-La Roche AG from February 2015 to July 2018. Ms. Feng served as the deputy chief human resources officer of Fosun High Technology and the managing director of the human resources of Shanghai Fosun Venture Capital Investment Management Co., Ltd. (上海複星創業投資管理有限公司) from July 2018 to April 2020. Ms. Feng has served as the vice president and the general manager of the human resources department of Fosun Pharmaceutical since April 2020. Ms. Feng has served as the chairman of the supervisory committee of Henlius since May 2020.

Mr. Zhuo Fumin, aged 69, is currently an independent non-executive Director of the Company. Mr. Zhuo has been an independent non-executive Director of the Company since March 2016. Mr. Zhuo has more than 44 years of experience in the field of enterprise management and capital markets. Mr. Zhuo graduated from Shanghai Jiaotong University of Engineering Science in 1983. He subsequently obtained a master's degree in economics from Fudan University in 1997. Mr. Zhuo currently serves as chairman and managing partner of V Star Capital. Between 1987 and 1995, Mr. Zhuo held senior positions including an office head and an officer assistant of the Shanghai Economic System Reform Committee. Between 1995 and 2002, Mr. Zhuo successively held various senior positions at Shanghai Industrial Investment (Holdings) Co., Ltd., including the managing director and chief executive officer of Shanghai Industrial Holdings Limited (a company listed on the Hong Kong Stock Exchange, stock code: 363) and the chairman of SIIC Medical Science and Technology (Group) Limited. Mr. Zhuo has served as the chairman and the chief executive officer of Vertex China Investment Co., Ltd. (a wholly owned subsidiary of Vertex Management Group, a global venture capital management company), founder and chairman of Shanghai Kexing Investment Co., Ltd. and managing partner of GGV Capital, a venture capital fund since 2002. Mr. Zhuo is also an independent director of Arcplus

9

Group Plc (a company listed on the Shanghai Stock Exchange, stock code: 600629) and Daqo

New Energy Corp. (a company listed on the New York Stock Exchange, stock code: DQ),

Focus Media (a company listed on the Shenzhen Stock Exchange, stock code: 002027), Shanghai Shine-Link International Logistics Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 603648) and Dazhong Transportation (Group) Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600611), a non-executive director of Besunyen Holdings Company Limited (a company listed on the Hong Kong Stock Exchange, stock code: 926), and an independent non-executive director of SRE Group Limited (a company listed on the Hong Kong Stock Exchange, stock code: 1207). The Board would like to supplement that notwithstanding Mr. Zhuo Fumin has served as a director on the board of directors of more than seven listed companies, he has maintained his professionalism in the directorships of listed companies he served, and has actively participated in the meetings of the Board and various special committees under the Board of the Company in the past. As such, his time committed for his director's duties is not affected. The Board (except Mr. Zhuo Fumin) unanimous agrees that Mr. Zhuo Fumin has devoted sufficient time to perform his director's duties and will continue to do so after his re-election.

Mr. Chen Fangruo, aged 55, is currently an independent non-executive Director of the Company. He has served as independent non-executive Director of the Company since he joined the Company in December 2018. Mr. Chen graduated from Shanghai Jiao Tong University in 1985 with dual Bachelor's Degrees in Shipbuilding and Marine Engineering and Computer Science and Technology. In 1987, he obtained a Master's Degree from the Moore School of Electrical Engineering, University of Pennsylvania. He then received his Ph.D. degree from the Wharton School at the University of Pennsylvania. Mr. Chen worked at Columbia Business School in 1992, successively serving as the Assistant Professor, Associate Professor, Lifetime Associate Professor, and Full Professor. In 2005, he became the Lifetime Chair Professor. During the foregoing period, Mr. Chen acted as a distinguished visiting professor at Stanford School of Business, Cheung Kong Graduate School of Business, Chinese Academy of Sciences, Shanghai Jiao Tong University, Peking University, Tianjin University and other prestigious universities at home and abroad. Mr. Chen has served as a visiting chair professor at Shanghai Jiao Tong University since 2017. He is currently a "Guangqi" fund sponsored professor at Shanghai Jiao Tong University, the Dean of Antai College of Economics and Management at Shanghai Jiao Tong University and the Dean of the Industry Research Institute of Shanghai Jiao Tong University. Since 2019, he has served concurrently as the vice chairman of the National MBA Education Instruction Committee and a director of the AMBA & BGA's International Management Board.

Mr. Li Peiyu, aged 57, is currently the managing director of CASIC Investment Fund Management (Beijing) Limited Company (航太科工投資基金管理(北京)有限公司). Mr. Li obtained a bachelor's degree of engineering in Power System and Automation from Tsinghua University, a master's degree of engineering in Management Engineering from the Department of Economics, School of Economics and Management, Tsinghua University, and PhD of management in Management Science and Engineering from School of Economics and Management, Tsinghua University in July 1984, July 1987 and January 2004, respectively, and obtained a Master of Public Administration (MPA) from Harvard University in June 1998. Mr. Li has worked in the areas of economics, finance and

10

management for more than 30 years. From July 1987 to September 2000, he successively served as associate researcher, researcher, deputy director and director of the Information Center of the Development Research Center of the State Council. From September 2000 to December 2007, Mr. Li successively served as the deputy director of Henan Provincial Development Planning Committee and the mayor of Hebi City in Henan Province. From December 2007 to January 2019, Mr. Li successively served as director of alternative investment department of China Investment Corporation, inspector of the research office of the State Council, chairman of China Reinsurance (Group) Corporation, and managing director of Beijing Zhongyu Green Investment Management Co., Ltd. Since February 2019, Mr. Li has served as the managing director of CASIC Investment Fund Management (Beijing) Limited Company.

Mr. Wu Tak Lung, aged 55. Mr. Wu received a bachelor's degree in Business Administration from

the Hong Kong Baptist University in 1993 and a master's degree in business administration jointly from the University of Manchester and the University of Wales in 2001. Mr. Wu currently serves as an independent non-executivedirector of Sinomax Group Limited (a company listed on the Hong Kong Stock Exchange, stock code: 1418), China Machinery Engineering Corporation (a company listed on the Hong Kong Stock Exchange, stock code: 1829), Kam Hing International Holdings Limited (a company listed on the Hong Kong Stock Exchange, stock code: 2307), Henan Jinma Energy Company Limited (a company listed on the Hong Kong Stock Exchange, stock code: 6885), Zhongguancun Science-Tech Leasing Co., Ltd. (a company listed on the Hong Kong Stock Exchange, stock code: 1601) and Minth Group Limited (a company listed on the Hong Kong Stock Exchange, stock code: 425). In the last three years from July 2017 to July 2020, Mr. Wu was an independent non-executivedirector of Sinotrans Shipping Limited (a company formerly listed on the Hong Kong Stock Exchange and delisted in January 2019, former stock code: 00368), Huarong Investment Stock Corporation Limited (a company listed on the Hong Kong Stock Exchange, stock code: 02277), First Tractor Company Limited (a company listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange, stock code: 00038 (H Share) / 601038 (A Share)), Olympic Circuit Technology Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 603920) and Beijing Media Corporation Limited (a company listed on the Hong Kong Stock Exchange, stock code: 1000). Mr. Wu had worked in Deloitte Touche Tohmatsu, an international accounting firm, for five years. Mr. Wu is currently a member of Hong Kong Institute of Certified Public Accountants, a fellow member of Hong Kong Securities and Investment Institute, the Association of Chartered Certified Accountants, the Taxation Institute of Hong Kong, and the Hong Kong Institute of Chartered Secretaries. The Board would like to supplement that notwithstanding Mr. Wu Tak Lung has served as a director of six Hong Kong listed companies in addition to serving as a director of the Company, the Board still believes that he can devote sufficient time to the Board and the Company for the following reasons: (1) as all directorships are independent and non-executive in nature, Mr. Wu is not involved in their daily operations and does not need to devote all time and energy to the affairs of these companies; (2) Mr. Wu has served as an independent non-executive director in many public companies over the past 13 years and has accumulated extensive experience in corporate governance and performance of the duties of an independent non-executive director; and (3) according to the published annual reports of the aforementioned listed companies, Mr. Wu has participated in substantially all board meetings of these companies during his tenure, and has no difficulty in

11

allocating time for the directorships. As such, the Board is of the view that Mr. Wu Tak Lung can still devote sufficient time and energy to the affairs of the Board despite he holds other directorships.

Mr. Yu Weifeng, aged 48, is a lawyer with more than 24 years of working experience as a practicing lawyer. Mr. Yu obtained a bachelor's degree in laws from Fudan University in June 1995 and a master's degree in business administration from China Europe International Business School in July 2015. In July 2019, he completed the Senior Management Leadership Program of Harvard Business School. From July 1995 to December 1998, Mr. Yu served as a paralegal and lawyer in Shanghai Pu Dong International Law Office (now renamed as Shanghai Pu Dong Law Office); Mr. Yu has served as a partner in Links Law Offices since December 1998, and served as a director thereof from January 2014 to June 2020. Since June 2020, Mr. Yu has served as an independent director of Deppon Logistics Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code :603056) and Shenergy Company Limited (a company listed on the Shanghai Stock Exchange, stock code: 600642). Currently, Mr. Yu is also an executive councillor of the All China Lawyers Association, director of Foreign Affairs Committee of the All China Lawyers Association, president of Shanghai Arbitration Association, a member of the Administrative Review Committee of Shanghai Municipal People's Government, special consultant of Shanghai Higher People's Court, an arbitrator of Shanghai International Economic and Trade Arbitration Commission (Shanghai International Arbitration Center), an arbitrator of Shanghai Arbitration Commission, etc.

As at the date of this announcement, Mr. Li Zhiming has an interest in 85,800 H shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong, same below). Mr. Yu Qingming and Mr. Liu Yong have interests in 100,000 and 69,300 H shares of the Company, respectively.

Save as disclosed above, none of the above Director candidates for the fifth session of the Board has any relationship with any Director, senior management or substantial or controlling Shareholder of the Company, or has any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, none of the above Director candidates for the fifth session of the Board held any other positions in the Company or any of its subsidiaries, or any directorships in other listed companies in the last three years.

Save as disclosed above, the Company is not aware of any other matters that need to be brought to the attention of the Shareholders or any information in relation to the appointment of the above Director candidates for the fifth session of the Board that need to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Hong Kong Listing Rules.

12

APPENDIX II BIOGRAPHIES OF THE SHAREHOLDER REPRESENTATIVE SUPERVISOR AND INDEPENDENT SUPERVISOR CANDIDATES FOR THE FIFTH SESSION OF THE SUPERVISORY COMMITTEE

Mr. Wu Yifang, aged 51, joined Fosun Pharma in April 2004 and is currently an executive director, president and chief executive officer of Fosun Pharma. Mr. Wu graduated from Nanjing University of Science and Technology majoring in international trade in June 1996 and obtained an executive master's degree in business administration (pharmaceutical marketing) from St. Joseph's University in September 2005. Mr. Wu was qualified as a senior economist. Mr. Wu served as the president, chairman and chief executive officer of Jiangsu Wanbang Biopharmaceuticals Group Co., Ltd from March 2007 to April 2011 and from April 2011 to June 2020, respectively. Mr. Wu has been a non- executive director of Henlius and Sisram Medical Ltd (a company listed on the Hong Kong Stock Exchange, stock code: 01696) since June 2015 and since October 2016, respectively. Mr. Wu is also currently a representative of the 13th National People's Congress of Jiangsu Province, an executive member of China Society for Drug Regulation (中國藥品監督管理研究會), a vice chairman of China News of Drug Information Association (中國醫藥新聞信息協會), a rotating chairman of China Nonprescription Medicines Association (中國非處方藥協會), a vice chairman of China Pharmaceutical Industry Association (中國化學製藥工業協會) and a vice chairman of China Pharmaceutical Enterprise Association ( 中 國 醫 藥 企 業 管 理 協 會 ), and others.

Mr. Liu Zhengdong, aged 50, is a lawyer who has more than 26 years of working experience as a practicing lawyer. Mr. Liu graduated from East China University of Political Science and Law (formerly known as East China School of Political Science and Law) with a bachelor's degree in Law in 1991, and juris master's degree in 2002. He served as an assistant prosecutor in Railway Transportation branch of Shanghai People's Procuratorate from July 1991 to June 1994. From June 1994 to October 1998, Mr. Liu worked at Shanghai Hongqiao Law Firm and has been serving as a lawyer. Mr. Liu co-founded Shanghai Junyue Law Firm with others in October 1998 and served as director and chief partner lawyer successively. Mr. Liu has been an independent non-executive Director of the Company since September 2014. Mr. Liu served as president of the Eighth Session of Shanghai Bar Association and was also honored as National Excellent Lawyer and Shanghai Excellent Non-litigation Lawyer. Currently, Mr. Liu serves as deputy to the Shanghai 15th People's Congress, director of the National Lawyers Association, president of Shanghai Bankruptcy Administrators Association ( 上海市破產管理人協會), and vice president of Shanghai General Chamber of Commerce. Mr. Liu also serves as a member of the legal experts of CPC Shanghai Committee (中共上海市委法律專家庫), arbitrators of China International Economic and Trade Arbitration Commission (CIETA), Shanghai International economic and Trade Arbitration Commission (SHIAC) and Shanghai Arbitration Commission (SAC).

Ms. Li Xiaojuan, aged 44, is currently a Supervisor of the Company. Ms. Li has served as a Supervisor of the Company since January 2016. Ms. Li has over 18 years of working experience. Ms. Li obtained a bachelor's degree in real estate operation and management from investment economics department of Dongbei University of Finance & Economics in July 1998 and a master's degree in national economics (investment economics) with specialty in securities investment from investment economics department of Dongbei University of Finance & Economics in April 2001. Ms. Li is a

13

senior economist, a non-practicing certified public accountant, and an asset valuer. Ms. Li served as the project manager of Beijing Tianhua Accounting Firm from April 2001 to April 2003 and the vice director of strategic cooperation department of TopSun Group from April 2003 to February 2005. Ms. Li served as the manager of finance department of China National Pharmaceutical Industry Corporation from February 2005 to April 2006 and the director of auditing and supervision office and the manager of auditing department of China National Pharmaceutical Industry Corporation from April 2006 to August 2010. Ms. Li joined CNPGC in August 2010 and served as the vice director of investment management department from August 2010 to April 2014. She served as vice director and director of auditing department from April 2014 to January 2019 and has served as director of finance department since January 2019. Ms. Li has served as the Chief Financial Officer of Sinopharm Investment since September 2019.

Save as disclosed above, none of the above shareholder representative Supervisor and independent Supervisor candidates for the fifth session of the Supervisory Committee has any relationship with any Director, senior management or substantial or controlling Shareholder of the Company, or have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, none of the above shareholder representative Supervisor and independent Supervisor candidates for the fifth session of the Supervisory Committee held any other positions in the Company or any of its subsidiaries, or any directorships in other listed companies in the last three years.

Save as disclosed above, the Company is not aware of any other matters that need to be brought to the attention of the Shareholders or any information in relation to the appointment of the above shareholder representative Supervisor and independent Supervisor candidates for the fifth session of the Supervisory Committee that need to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Hong Kong Listing Rules.

14